Longer follow-up on cardiac safety and distant disease free survival of dose-dense doxorubicin and cyclophosphamide followed by paclitaxel and trastuzumab in patients with early-stage HER2-positive breast cancer.

Authors

Rui Wang

Memorial Sloan Kettering Cancer Center, New York, NY

Rui Wang , Anthony Francis Yu , Richard Steingart , Sujata Patil , Jose Baselga , Larry Norton , Cliff Hudis , Chau T. Dang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2013 Breast Cancer Symposium

bookmark_border

Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).

First Author: Neil M. Iyengar

insert_chart_outlined

Poster

2013 ASCO Annual Meeting

bookmark_border

Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).

First Author: Patrick Glyn Morris

insert_chart_outlined

Poster

2011 ASCO Annual Meeting

bookmark_border

Long-term cardiac safety and outcomes of dose-dense (dd) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H) with and without lapatinib (L) in patients (pts) with early breast cancer (BC).

First Author: C. T. Dang

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.

First Author: Kay T Yeung